DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lotensin (Benazepril Hydrochloride) - Published Studies


Lotensin Related Published Studies

Well-designed clinical trials related to Lotensin (Benazepril)

Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. [2011.02]

[Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study]. [2011.01]

Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. [2010.06]

A randomized controlled clinical trial of the use of benazepril and heparin for the treatment of chronic kidney disease in dogs. [2009.04.15]

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. [2008.12.04]

An eight-week, multicenter, randomized, double-blind study to evaluate the efficacy and tolerability of fixed-dose amlodipine/benazepril combination in comparison with amlodipine as first-line therapy in chinese patients with mild to moderate hypertension. [2008.06]

Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study. [2007.07]

The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. [2007.03]

Evaluation of the clinical efficacy of benazepril in the treatment of chronic renal insufficiency in cats. [2006.09]

Benazepril and subclinical feline hypertrophic cardiomyopathy: a prospective, blinded, controlled study. [2006.05]

Efficacy of combination therapy with amlodipine besylate/benazepril hydrochloride for lowering systolic blood pressure in stage 2 hypertension. [2006.05]

An open-label, randomized, controlled, 4-week comparative clinical trial of barnidipine hydrochloride, a calcium-channel blocker, and benazepril, an angiotensin-converting enzyme inhibitor, in Chinese patients with renal parenchymal hypertension. [2006.03]

Efficacy and safety of benazepril for advanced chronic renal insufficiency. [2006.01.12]

A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. [2006]

Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. [2004.07]

Effects of co-administration of urokinase and benazepril on severe IgA nephropathy. [2004.04]

Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. [2003.08]

Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension. [2003.04]

Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. [2003.03]

Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats. [2002.10]

Comparison of benazepril-amlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension. [2002.06]

Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. [2001.11]

Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. [2001.07]

Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. [2001.07]

Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. [2000.12.01]

[Evaluation on the effect of Benazepril for hypertension through postmarketing surveillance] [2000.06]

Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. [2000.01]

Benazepril causes in hypertension a greater reduction in left ventricular mass than does nitrendipine: a randomized study using magnetic resonance imaging. [1998.11]

Effect of benazepril on complex ventricular arrhythmias in older patients with congestive heart failure, prior myocardial infarction, and normal left ventricular ejection fraction. [1998.06.01]

[Antihypertensive action and predictive factors of efficacy of benazepril in mild-to-moderate hypertension: clinical trial in general medical practice on 16,987 patients] [1998.01]

[Effects of lotensin and nitrendipine on plasma fibrinogen and platelet aggregation in hypertensive patients] [1998]

Benazepril, an angiotensin converting enzyme inhibitor: drug interaction with salbutamol and bronchial response to histamine in normal subjects. [1997.12]

Economic evaluation of benazepril in chronic renal insufficiency. [1997.12]

Combined therapy with benazepril and amlodipine in the treatment of hypertension inadequately controlled by an ACE inhibitor alone. [1997.10]

Fixed combination of benazepril and low-dose amlodipine in the treatment of mild to moderate essential hypertension: evaluation by 24-hour noninvasive ambulatory blood pressure monitoring. [1997.08]

Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. [1996.11]

Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes. [1996.10]

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. [1996.04.11]

Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. [1996.01]

Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. [1995.11]

Short-term and long-term effects of benazepril in mild to moderate hypertensives. [1995.07]

[Comparison of blood pressure profile during exercise with benazepril 10 mg and benazepril 5 mg/hydrochlorothiazide 6.25 mg fixed combination] [1995.07]

Fixed combination of benazepril and very low dose hydrochlorothiazide in the treatment of mild to moderate essential hypertension: evaluation by 24-hour non invasive ambulatory blood pressure monitoring. [1994.11]

Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of benazepril 20 mg plus hydrochlorothiazide 25 mg fixed combination as compared to captopril 50 mg [corrected] plus hydrochlorothiazide 25 mg fixed combination in treating mild to moderate hypertension: a double-blind, within-patient, placebo-controlled study. [1994.11]

Efficacy and safety of benazepril plus hydrochlorothiazide versus benazepril alone in hypertensive patients unresponsive to benazepril monotherapy. [1994.11]

The absence of a pharmacokinetic interaction between aspirin and the angiotensin-converting enzyme inhibitor benazepril in healthy volunteers. [1994.08]

Effect of combination therapy with atenolol and the angiotensin-converting enzyme inhibitor benazepril. [1994.05]

[Efficacy of benazepril after failure of the first antihypertensive treatment] [1994.03]

Effects of benazepril on stress testing blood pressure in essential hypertension. [1994.02.15]

Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. [1994]

[Multicenter comparative study of the effects of benazepril and captopril in mild and moderate systemic hypertension] [1993.12]

Influence of benazepril and captopril on blood pressure, glucocorticoids and progesterone in essential hypertensives. [1993.12]

The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril. [1993.09]

Effects of the single and repeated administration of benazepril on systemic and forearm circulation and cardiac function in hypertensive patients. [1993.04]

Reduction of exercise-induced ventricular arrhythmias in mild symptomatic heart failure by benazepril. [1993.03]

Unmasking of the hypotensive effect of nifedipine in normotensives by addition of the angiotensin converting enzyme inhibitor benazepril. [1992.09]

Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. The Benazepril Heart Failure Study Group. [1992.08.01]

Effect of benazepril on myocardial ischaemia in patients with chronic stable angina pectoris. [1992.08]

Short-term metabolic effects of the ACE-inhibitor benazepril in type 2 diabetes mellitus associated with arterial hypertension. [1992.07]

A 3-month double-blind cross-over study of the effect of benazepril and hydrochlorothiazide on functional class in symptomatic mild heart failure. [1992.06]

Sympathomoderating influence of benazepril in essential hypertension. [1992.04]

[Effects of benazepril, a new ACE inhibitor, in effort angina pectoris] [1991.10]

Effects of the angiotensin converting enzyme inhibitor, benazepril, on the sino-aortic baroreceptor heart rate reflex. [1991.08]

Converting enzyme inhibition in coronary artery disease: a randomized, placebo-controlled trial with benazepril. [1991.05]

The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: a multicenter study. [1991.03]

Diurnal blood pressure in patients with mild-to-moderate hypertension treated with once-daily benazepril hydrochloride. [1990.05]

Benazepril at incremental doses in essential hypertension. [1990.02]

Blunting of atrial natriuretic factor response to volume expansion by benazepril in hypertensive patients. [1989.12]

Definition of the effective dose of the converting-enzyme inhibitor benazepril. [1989.03]

Well-designed clinical trials possibly related to Lotensin (Benazepril)

High level of proteinuria during treatment with renin-angiotensin inhibitors is a strong predictor of renal outcome in nondiabetic kidney disease. [2011.07]

Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial. [2010.11]

Cardiovascular events during differing hypertension therapies in patients with diabetes. [2010.06.29]

Role of RAS inhibition in the regulation of Cu/Zn-SOD in the cardiac and peripheral arterial beds in humans. [2010.06]

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. [2010.04.03]

Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. [2008.10]

Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker. [2008.09]

The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. [2008.09]

Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. [2008.06]

Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. [2008.03.19]

Intron-2 conversion polymorphism of the aldosterone synthase gene and the antihypertensive response to angiotensin-converting enzyme inhibitors. [2008.02]

Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis. [2008.02]

Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. [2008]

[Clinical observation on treatment of hypertension (yin-deficiency with sthenic-yang syndrome type) with zhongfu hypotension capsule] [2007.08]

IgACE: A Placebo-Controlled, Randomized Trial of Angiotensin-Converting Enzyme Inhibitors in Children and Young People with IgA Nephropathy and Moderate Proteinuria. [2007.06]

Exceptional early blood pressure control rates: the ACCOMPLISH trial. [2007]

Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors. [2006.06]

A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. [2006]

T1198C polymorphism of the angiotensinogen gene and antihypertensive response to angiotensin-converting enzyme inhibitors. [2005.12]

Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. [2005.11]

[Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L?] [2005.08]

[Effect of triptolide on urinary monocyte chemottractant protein-1 in patients with diabetic nephropathy] [2005.05]

Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. [2005.04]

Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. [2005.03]

Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. [2005.02]

Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. [2004.06]

Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. [2004.02]

Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. [2004.01]

Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients. [2003.11]

Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. [2003.05]

Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. [2003.04]

Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. [2003.03]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017